Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis

Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis

ABSTRACT This study aimed to investigate the efficacy, safety, and predictors of camrelizumab combined with carboplatin and nab‐paclitaxel as first‐line setting for patients with extensive‐stage small‐cell lung cancer (ES‐SCLC). Camrelizumab plus carboplatin and nab‐paclitaxel were administrated eve...

Full description

Saved in:
Bibliographic Details
Main Authors: Jia Yu, Deyu Cai, Sha Zhao, Lei Wang, Xinlong Zheng, Anwen Xiong, Qi Wang, Bin Chen, Menghang Yang, Wei Li, Yan Wang, Jiajia Yuan, Changhong Zhao, Wei Shi, Caicun Zhou, Luonan Chen, Tao Jiang, Xiaohui Chen, Shengxiang Ren
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:MedComm
Subjects:
biomarker
camrelizumab
ES‐SCLC
immunotherapy
nab‐paclitaxel
Online Access:https://doi.org/10.1002/mco2.70300
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/mco2.70300

Similar Items